SWOG clinical trial number
S2417CD
A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance
Open
Phase
Accrual
2%
Abbreviated Title
CRC Surveillance
Status Notes
This study is open to accrual, effective 8/4/2025 at 12:00 p.m. PT.
Activated
08/04/2025
Research committees
Cancer Care Delivery
Gastrointestinal Cancer
Patient Study Materials
Patient Clinical Trial Summary
Download PDF of Patient Clinical Trial Summary
Eligibility Criteria Expand/Collapse
Patient Participant Eligibility Criteria
- must have newly diagnosed surgically resected, Stage II or Stage III colorectal cancer (CRC) and be registered within 90 - 180 days of surgical resection;
- must have an adult in their life who supports them in their CRC journey who might be willing to join them in viewing an educational website;
- must be >/= 18 years of age at the time of registration/randomization;
- must have Zubrod Performance Status of 0-2;
- must be able to read English or Spanish since the website for the intervention and control arm are available in English and Spanish;
- must be able to complete PROs in English or Spanish and agree to complete them at all scheduled timepoints;
- participants will be encouraged to provide an email address or cell phone number, if possible, for the purpose of being contacted by staff at the University of Michigan who will provide access to the educational website. (For those who do not wish to provide or create an email address or a cell phone number, they may still participate with alternate methods);
- must not have recurrent or metastatic (Stage IV) CRC;
- must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the efficacy assessment of this intervention;
- must not be enrolled or be planning to enroll in a clinical trial of investigational treatment that includes imaging and/or laboratory monitoring for the duration of this trial.
Supporter Participant Eligibility Criteria
- must be >/= 18 years of age at the time of registration/randomization;
- must be able to read English or Spanish since the educational website is available in English and Spanish;
- must have been identified by the patient as a person who may be willing to join them in reviewing the educational website.
- must have newly diagnosed surgically resected, Stage II or Stage III colorectal cancer (CRC) and be registered within 90 - 180 days of surgical resection;
- must have an adult in their life who supports them in their CRC journey who might be willing to join them in viewing an educational website;
- must be >/= 18 years of age at the time of registration/randomization;
- must have Zubrod Performance Status of 0-2;
- must be able to read English or Spanish since the website for the intervention and control arm are available in English and Spanish;
- must be able to complete PROs in English or Spanish and agree to complete them at all scheduled timepoints;
- participants will be encouraged to provide an email address or cell phone number, if possible, for the purpose of being contacted by staff at the University of Michigan who will provide access to the educational website. (For those who do not wish to provide or create an email address or a cell phone number, they may still participate with alternate methods);
- must not have recurrent or metastatic (Stage IV) CRC;
- must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the efficacy assessment of this intervention;
- must not be enrolled or be planning to enroll in a clinical trial of investigational treatment that includes imaging and/or laboratory monitoring for the duration of this trial.
Supporter Participant Eligibility Criteria
- must be >/= 18 years of age at the time of registration/randomization;
- must be able to read English or Spanish since the educational website is available in English and Spanish;
- must have been identified by the patient as a person who may be willing to join them in reviewing the educational website.
Other Clinical Trials
SWOG Clinical Trial Number
S2303
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
Phase
SWOG Clinical Trial Number
S2104
A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
54%
Open
Phase